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Background: Generalized anxiety disorder is the most common mental health condition
based on weekly prevalence. Digital interventions have been used as alternatives or
as supplements to conventional therapies to improve access, patient choice, and
clinical outcomes. Little is known about their comparative effectiveness for generalized
anxiety disorder.
Methods: We conducted a systematic review and network meta-analysis of randomized
controlled trials comparing digital interventions with medication, non-digital interventions,
non-therapeutic controls, and no intervention.
Results: We included 21 randomized controlled trials with a total of 2,350 participants
from generalized anxiety disorder populations. Pooled outcomes using analysis of
Covariance and rankograms based on the surface under the cumulative ranking curves
indicated that antidepressant medication and group therapy had a higher probability than
digital interventions of being the “best” intervention. Supported digital interventions were
not necessarily “better” than unsupported (pure self-help) ones.
Conclusions: Due to very wide confidence intervals, network meta-analysis results
were inconclusive as to whether digital interventions are better than no intervention and
non-therapeutic active controls, or whether they confer an additional benefit to standard
therapy. Future research needs to compare digital interventions with one-to-one therapy
and with manualized non-digital self-help and to include antidepressant medication as a
treatment comparator and effect modifier.
Keywords: worry, anxiety, cognitive behavior therapy (CBT), mobile applications, digital, systematic review (sr),
meta-analysis
INTRODUCTION
Generalized Anxiety Disorder (GAD) is the most commonmental health condition with 6% point-
prevalence (measured over the preceding week) in the UK, nearly double that of depression (3.3%)
(1). It is often confused with panic disorder or depression when self-reported by survey participants
(2). GAD is characterized by excessive worry that persists for several months and leads to significant
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distress or impairment in everyday life and functioning (3). Other
typical characteristics include free-floating anxiety and physical
symptoms, such as muscle tension, headaches, restlessness,
difficulty concentrating, irritability, or sleep problems. GAD is
associated with low quality of life and high healthcare costs (4).
Psychological interventions can be effective for GAD,
especially cognitive behavior therapy (CBT) (5) and applied
relaxation (6). CBT helps the individual challenge or tolerate
worrying thoughts and confront anxiety-provoking situations
rather than avoiding them. Applied relaxation counteracts the
physical symptoms of GAD thought a series of tense-then-release
muscle exercises that reduce muscle tension. Antidepressant
medication can also be effective (7) and is often the first
choice for treatment by clinicians in view of limited capacity
to deliver psychological interventions. To improve access to
psychological therapies and increase patient choice and therapist
capacity, digital interventions have been used as alternatives or
supplements to conventional face-to-face clinic-based therapy
(8, 9).
Digital interventions are defined as software-based
therapeutic activities accessed via technology platforms, such
as the internet, virtual reality (VR), mobile phones. According
to the World Health Organization (WHO), the term “digital
intervention” represents a discrete function of using technology
to achieve health sector objectives (10). In the context of a
specific condition, such as GAD, digital intervention (DIs) fulfil
the discrete function of using software and digital media to
deliver therapeutic activities that aim to improve symptoms
associated with the condition in populations.
An example of a DI for GAD is a 10-week internet-based self-
help programme consisting of psychoeducation (information
about worry, stress, and anxiety, including its risk factors and
treatments), CBT (dealing with the purpose, meaning, and
content of worry, as well as modifying unhelpful responses to
worry), relaxation (tensing then releasing body muscle groups
and refocus attention away from worry) and physical activity
(11). Another example is a mobile app (12) that teaches
diaphragmatic breathing in a series of mini-games, from sailing a
boat down a river to flying balloons into the sky.
Previous reviews of the effectiveness of DIs for GAD (13, 14)
included mixed populations of anxiety disorders and depression
without reporting outcomes separately for GAD subgroups
within these mixed samples. Reporting a disorder-specific
outcome for mixed samples can be misleading because it implies
that, if an intervention works for the mixed sample, it will also
work for each of its constituent populations. Studies reporting
findings from mixed samples do not answer the question of
whether DIs are effective for GAD to inform disorder-specific
clinical guidelines. To achieve this, and while preserving the
benefits of randomisation, we need to analyse GAD outcomes
reported separately for GAD populations and GAD sub-samples
within mixed populations.
This paper reports a systematic review and quantitative
synthesis of RCTs comparing DIs with other interventions,
non-therapeutic control arms and no intervention for GAD
populations with varying levels of illness severity (sub-threshold,
mild, moderate, severe). The review had four objectives:
1. Categorize the DIs and comparator arms into groups that
could be pooled together.
2. Compare the pooled outcomes of DIs with the pooled
outcomes of non-digital interventions, medication, non-
therapeutic controls, and no intervention for GAD symptoms.
3. Compare the pooled outcomes of different types of DIs.
4. Identify limitations and gaps in the existing research on DIs
for GAD.
After describing the review, the classification and synthesis
methodology in section Methods, section Results of the paper
goes through the characteristics of the evidence base and
synthesis results. Section Discussion discusses the findings,
followed by concluding remarks in section Conclusions.
METHODS
Protocol
The protocol for the review was registered with PROSPERO
2018 CRD42018105837 as part of a larger piece of work that
investigated the costs and outcomes of digital interventions for
mental health, funded by the UK’s National Institute for Health
Research (NIHR). The review has been conducted and reported
as recommended by the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) extension statement for
network meta-analysis (15).
Search Strategy
In December 2018, the following databases were searched
to identify published and unpublished studies: MEDLINE,
PsycINFO, Cochrane Central Register of Controlled Trials
(CENTRAL), Cochrane Database of Systematic Reviews (CDSR),
Cumulative Index to Nursing & Allied Health (CINAHL
Plus), Database of Abstracts of Reviews of Effects (DARE),
EMBASE, Web of Science Core Collection, NHS Economic
Evaluation Database (NHS EED); Database of promoting health
effectiveness reviews (DoPHER) and Proquest.
We also searched two clinical trial registries and other
resources for ongoing studies: ClinicalTrials.gov and the WHO
International Clinical Trials Registry Platform portal, as well as
the NIHR portfolio of studies. Web searches were conducted
using Google and Google Scholar making use of simplified search
terms. After searches were complete, supplementary searches
were conducted, including reference lists of included studies and
forward citation searches. Finally, we contacted the authors of
included studies for information on any other work in the field
they were aware of. The searches were undertaken for studies
conducted since 1997 and restricted to those written in English.
In June 2019, the searches were updated and widened to
include terms based on unspecified Anxiety Disorders. An
additional pilot search was conducted on Cochrane Library and
PsycINFO databases using terms based on “worry” and “anxiety
prevention.” This ensured that no articles were missed. No new
included articles emerged from the pilot search, and it was not
deemed necessary to expand it to all remaining databases. The full
search terms and outputs of the database searches are provided
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in Appendix A (December 2018 search) and Appendix B (June
2019 search).
Study Identification and Selection
Two reviewers (DM, HM) independently screened all titles and
abstracts of the identified studies against our inclusion/exclusion
criteria. If either reviewer indicated a study could be relevant,
we retrieved the full text. The same two reviewers independently
assessed the full texts against our inclusion/exclusion
criteria. A third reviewer (LG) resolved any disagreements
through discussion to agree a final list of included and
excluded studies.
Eligible studies included: (a) study design: RCTs, to minimize
risk of bias and confounding variables; (b) participants:
participants with symptoms or risk of GAD within mental
health populations or within the general population; we defined
this as a certified diagnosis using a standardized diagnostic
interview or a score above an accepted cut-off for diagnosable
GAD (which may include sub-threshold scores) in standardized
questionnaires; (c) interventions: software-based systems and
technology platforms designed for patient-facing delivery of a
mental health intervention (i.e., an intervention to improve
mental health outcomes); (d) comparisons: all comparisons
relevant to DIs, even when two or more DIs were compared
with each other without other comparators; and (e) outcomes:
GAD-specific measures of anxiety or worry (e.g., GAD-7),
reported for GAD populations or GAD sub-samples within
mixed populations.
We have excluded: (i) mixed populations of GAD with other
conditions, when the outcomes were not reported separately
for GAD subgroups; (ii) technology used as a means for
telecommunication (e.g., email, phone or video) without any
software-based processing; (iii) software-based systems designed
for training of health professionals or for administration without
any patient-facing intervention components; and (iv) studies that
were only identified as protocols, abstracts, or reviews; these were
marked so we could check for RCTs that we may have missed in
the database searches.
Data Extraction and Risk of Bias
Assessment
Two researchers (DM, HM) independently extracted data
from published and unpublished study reports. Data were
extracted on the sample, study design, intervention, and
comparator characteristics, baseline characteristics, and results.
Any discrepancies were resolved by a third reviewer (LG). Risk
of bias of each study was assessed using Cochrane’s Risk of Bias
(RoB) 2.0 (16).
Classification of DIs and Their Alternatives
In order to conduct an evidence synthesis, it was necessary to
classify and group the interventions from studies. We developed
a classification system for DIs and their comparator interventions
and controls, in the following four steps:
a) We conducted a detailed data extraction of
intervention/control arm characteristics as reported within
our included RCTs for GAD and their relevant linked papers.
b) We identified common and differentiating features of
intervention/control arms between RCTs, but also
incremental differences between interventions/controls
within the same RCT.
c) We consulted the literature and an advisory group of health
services researchers and clinicians about intervention features
that could be important for clinical outcomes (e.g., amount
of interpersonal contact, who offers support to the DI,
whether the intervention is available publicly or via referral
to specialist services, types of software required or therapeutic
approaches used).
d) We applied the classification criteria to each randomisation
arm in the included RCTs so that each intervention/control
arm was assigned to a classification group.
These 4 steps were iterative; we resolved discrepancies by
refining our classification criteria until two reviewers (DM,
LG) independently reached the same allocation for every
intervention/control they classified. We grouped DIs and their
alternatives according to the three criteria below.
Criterion 1–Intervention (I) or Control (C): An Intervention
(I) was an action carried out as part of a research protocol
for therapeutic purposes, i.e., it was expected to improve
clinical symptoms and functioning based on psychological or
behavioral theories and preliminary evidence. A Control (C)
was a non-therapeutic activity that was not expected to make a
clinical difference to the condition; this could be a psychological
placebo, an “attention control,” or a change in usual care
introduced by the research team to keep participants safe and
minimize attrition.
Criterion 2–Digital (D) or Non-Digital (NoD): A Digital
Intervention (DI) or a Digital Control (DC) included software
programmes to guide patient-facing activities. A Non-Digital
Intervention/Non-Digital Control (NoDI/NoDC) did not
involve any technology and was delivered by printed materials
or during face-to-face meetings, or via telecommunications
technology without automated software e.g., consultations by
email, skype, or phone.
Criterion 3–Supported (S) or Unsupported (U): Supported
interventions/controls included scheduled or regular two-
way person-to-person contact (e.g., between service user
and clinician or researcher, or peer-to-peer). Unsupported
interventions/controls either had no interpersonal contact
or included limited ad-hoc interaction (e.g., phoning a
helpline with any problems as a one-off). We also classified
as unsupported interventions/controls those in which
communication was one-way, such as a reminders by email,
post, or phone.
Based on these three criteria, we mapped DIs and their
alternatives into eight groups resulting from the combinations of
(I or C) x (D or NoD) x (S or U).
Group 1: Supported Digital Intervention (SDI), e.g.,
computerized cognitive behavior therapy with phone support;
clinician-delivered therapy assisted by virtual reality.
Group 2: Unsupported Digital Intervention (UDI), e.g., internet
self-help without any clinician contact, mobile app with
automated reminders but without personal interaction.
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Group 3: Supported Non-Digital Intervention (SNoDI), e.g.,
individual or group therapy in a clinic, or therapy delivered by
a clinician via phone or an online platform.
Group 4: Unsupported Non-Digital Intervention (UNoDI), e.g.,
self-help using a treatment manual or a book or a website
without clinician input.
Group 5: Supported Digital Control (SDC), e.g., access to a
general health education website with weekly check-in calls
from a researcher; virtual reality “placebo” environment used
in a clinic with a researcher present.
Group 6: Unsupported Digital Control (UDC), e.g., access to an
educational website without any support from a person or with
just automated reminder emails.
Group 7: Supported Non-Digital Control (SNoDC), e.g., weekly
check-in by phone or regular clinical assessment face-to-face
without any specific therapy instructions.
Group 8: Unsupported Non-Digital Controls (UnoDC), e.g.,
printed materials with general health advice without any
specific therapy instructions.
Separate groups were used for medication and no intervention.
Medication (M) was any pharmacological agent (pills, injections,
etc.) offered as part of a research protocol. No Intervention
(NI) included waiting lists and usual care in which there were
no additional therapeutic activities and no changes in patient
routines. The NI group may still have received medication or
consultations as part of routine care, but this would have been
equally accessible to all participants in a trial irrespective of
group allocation, so the effect would be canceled out across
randomisation arms.
Data Synthesis and Statistical Analysis
Over the last two decades, network meta-analysis (NMA)
methods (17) also known as mixed treatment comparisons
(18, 19)–have been developed to synthesize evidence from
multiple studies. NMA is an extension to the standard
(pairwise) meta-analysis, which pools together the results
of studies for one type of intervention compared to one
type of alternative (e.g., active treatment or placebo control).
An NMA enables the simultaneous comparison of multiple
interventions and multiple comparators within a single coherent
analysis. Such an approach is routinely used in health
technology assessments to inform the optimal intervention
strategy for a given medical condition (20). NMAs are often
used to inform estimates of clinical and cost-effectiveness and
commissioning decisions.
In the NMA, an ANalysis of COVAriance (ANCOVA)
modeling framework was used, where a final outcome
measurement is synthesized and adjusted for baseline
measurements. Compared to the “change from baseline”
approach, the ANCOVA model avoids guessing within-patient
correlation across measurements as typically this is not reported
in studies. Treatment effect estimates based on ANCOVA
methods have been shown to be more efficient, less biassed
and robust to random baseline imbalance (21–26). Hence,
the ANCOVA model, is the preferred method for estimating
treatment effects from continuous outcomes (27–30).
We adopted a modeling approach in line with the
parameterisation for continuous data with normal likelihood
and identity link used by Dias et al. (21, 22). Fixed-effects (FE)
and random-effects (RE) models (the latter accounting for
potential correlation within multi-arm trials) were fit to the data.
In the model, patients who did not receive any treatment were
assumed to neither improve nor worsen over the duration (i.e.,
null placebo effect). Furthermore, it was assumed that the effect
of the baseline measurement is common across all treatments,
implying that when two active treatments are compared in a
trial, the baseline effects are offset.
All analyses were conducted within a Bayesian Markov
chain Monte Carlo (MCMC) approach, fitted using WinBUGS
software version 1.4.3 [Copyright © 2007 Medical Research
Council (UK) and Imperial College (UK)] (31) and linked to
the freely available software R [version 4.0.2, Copyright © 2020
(32)] through the package R2WinBUGS (33). In all models the
MCMC Gibbs sampler was initially run for 10,000 iterations
and these were discarded as “burn-in.” Models were run for
at least further 5,000 iterations, on which inferences were
based. Chain convergence was checked using autocorrelation and
Brooks-Gelman-Rubin diagram diagnostics (34–36). Goodness
of fit and model complexity was assessed using the deviance
information criterion (DIC) and posterior mean residual
deviance (37).
We presented the estimated results as relative treatment
effect scores and associated 95% credible intervals, CrIs. We
have estimated the probability of a treatment being the “best”
(i.e., being the most clinically effective) (38), and presented
rankograms for all interventions, which provide the probabilities
of an intervention being ranked 1 (the most effective) to 7
(the least effective). Finally, we reported the surface under
the cumulative ranking curve (SUCRA), which is a numerical
presentation of the overall ranking of each intervention. SUCRA
values range from 0 to 100%, with higher SUCRA values
suggesting that a treatment is likely to be better overall (21, 39).
Appendix C gives further details on the analysis (C1),
including annotated synthesis WinBUGS code (C2), sample data
and initial values for the main model used (C3).
Assessment of Heterogeneity and
Consistency
The model was extended to include study-level covariates
as potential treatment effect modifiers. This meant that we
looked for factors other than the treatment itself, which could
have influenced outcomes within each study and may have
created differences (heterogeneity) across studies. These factors
included disease severity (40), concomitant medication (41) and
the presence of comorbidities (42, 43). Meta-regression is the
most commonly employed method to explore the influence of
particular study-level covariates on the relative effect. To preserve
all studies (and treatments), when a covariate was not reported by
some studies, we allowed the model to impute missing covariate
information (multiple imputation procedure assuming “missing
at random”).
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We assessed inconsistency to check that all pieces of evidence
(from direct and indirect sources) were in agreement. Following
guidance by Dias and colleagues (44, 45), inconsistency was
assessed by comparing the DIC of our primary analyses
(based on NMA models that assume consistency between
direct and indirect evidence) and the DICs yielded by
inconsistency models (which provide effect estimates
based on direct evidence only). Results were assessed for
coherence by qualitatively comparing estimates of pairwise
ANCOVA meta-analysis (direct) and ANCOVA RE NMA
(direct and indirect).
Sensitivity Analysis
We conducted two types of sensitivity analysis. First, we
evaluated the sensitivity of the networks to the influence of each
individual trial. When network links were informed by more
than one trial, we removed each trial one at a time (giving
nj−1 for each analysis, where n is the total number of trials in
contrast j) and investigated the impact on the probability of each
intervention being “best.” Second, we assessed the robustness of
the synthesis results by repeating the analysis while excluding all
studies of <30 patients.
RESULTS
Included and Excluded Studies
Initial systematic searches of bibliographic databases identified
16,272 records; in addition, 32 records were identified through
secondary searches (e.g., citation searching of protocols and
abstracts). After duplicates were removed, a total of 8,920 records
were screened by title and abstract and 8,560 records were
excluded. We retrieved the full text papers for the remaining
377 records and, as a result of further screening, 352 articles
were excluded. In total, 21 studies (reported in 25 papers)
were included in the review. The PRISMA diagram (Figure 1)
summarisez the number of records retrieved and selected at
different stages of identification and screening.Appendix D gives
a full reference list of the excluded studies grouped according to
reasons for exclusion.
Sample Characteristics in RCTs of DIs for
GAD
The 21 RCTs included in the review, as detailed in Table 1,
were conducted over 10 years between 2009 and 2019 in 10
countries (Sweden, Australia, USA, UK, Canada, Spain, Italy,
Ireland, Taiwan, Netherlands) and involved 2,547 randomized
participants. Most participants were recruited from the adult
general population, except in four studies that recruited
students/young adults and one study with over 60s. GAD
populations were defined as either meeting the criteria of
an established diagnostic tool, such as the Mini-International
Neuropsychiatric Interview (MINI) (69), or a score above
an accepted cut-off for diagnosable GAD in standardized
questionnaires, such as the Generalized Anxiety Disorder-7 item
questionnaire (GAD-7) (40).
Risk of Bias Assessment
All but one (52) out of the 21 included studies, were judged to
have a high risk of bias in at least one domain of assessment,
for at least one outcome measure. This was largely due to the
choice of outcomemeasurement as all studies used self-reported–
albeit standardized–questionnaires. Self-reported outcomes are
considered to have a high risk of bias in these studies because
participants can rarely be blind to their allocation group. A
visual description of the results of the RoB assessment is given
in Appendix E, both for each RoB domain across all studies
(Appendix E1) and for each study under each RoB domain
(Appendix E2).
Classification of Digital Interventions and
Comparators
A classification exercise took place to enable consistency
across digital interventions and comparators. We classified
DIs and their alternatives according to three criteria: (a)
whether they were a psychological/behavioral intervention (I)
or a non-therapeutic psychological/behavioral control (C); (b)
whether they were digital (D) or non-digital (NoD); (c)
whether they were supported (S) or unsupported (U). Waiting
lists and usual care were classified under no intervention
(NI) unless an active component (e.g., monitoring, sham
activity) was introduced, in which case the waiting list/usual
care was classified as non-therapeutic psychological/behavioral
control. An additional classification group was included for
pharmacological interventions, called medication (M).
The interventions and controls of the 20 RCTs were
allocated to one of the following eight classification groups:
medication (M); no intervention (NI); supported digital control
(SDC); supported digital intervention (SDI); supported non-
digital control (SNoDC); supported non-digital intervention
(SNoDI); unsupported digital control (UDC); unsupported
digital intervention (UDI). There were no available clinical
studies that included unsupported non-digital interventions
(UNoDI) or unsupported non-digital controls (UNoDC).
Table 2 describes all the interventions and controls included in
each classification group for each study.
Based on the 8-group classification for GAD RCTs, the
majority of DIs studied were supported (SDI−18 RCTs) and
were compared against no intervention (NI−12 RCTs). Only 3
RCTs evaluated unsupported DIs (UDI); two were web-based
CBT (11, 51); and one (Pham et al.) a mobile game to practice
breathing re-training. The only non-digital intervention (NoDI)
represented in two RCTs (57, 68) was group therapy (one CBT
and one mindfulness-based intervention) and there was only one
RCT that included an antidepressant medication, Sertraline (49).
With regards to non-therapeutic active controls reported in 8
RCTs, most included a digital element whereas only one RCT
(64) had a non-digital control in the form of a weekly face-to-face
assessment with a research assistant in a lab (SDC).
Just over half of the included RCTs (12/21) evaluated
CBT. Therapeutic approaches other than CBT included:
psychodynamic therapy (47), extinction therapy (48), acceptance
and commitment therapy (50), cognitive or attentional bias
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FIGURE 1 | PRISMA diagram for the identification and selection of clinical trials relating to digital interventions for generalized anxiety disorder (GAD). Adapted from
Moher (46).
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TABLE 1 | Sample characteristics and outcome measurement in RCTs of digital interventions for GAD.





































Dahlin et al. (50) Sweden General–adults GAD diagnosis on SCID-I
PSWQ > 45





Dear et al. (51) Australia General–adults GAD diagnosis on MINI
GAD7>5







Hazen et al. (52) USA University students PSWQ > 60 24 23 3-6 weeks PSWQ, BDI, STAI-T
Hirsch et al. (53) UK General–adults Mixed sample
anxiety/depression#
GAD diagnosis on SCID-I
GAD7 > 10




Howell et al. (54) USA University students Mixed sample non-clinical
(GAD < 4) and clinical mild
GAD (4 < GAD7 < 10) ∼
197 NR 3 months GAD-7♦
Johansson et al.
(55)
Sweden General–adults Mixed sample
anxiety/depression#
GAD diagnosis on MINI
GAD7 > 10
43 NR 10 weeks
3 months
GAD-7, PHQ-9
Jones et al. (56) Canada Over 60s GAD diagnosis or threshold
sub-clinical on MINI
GAD7>10
46 41 7–10 weeks
1 month





Spain Primary care–adults GAD diagnosis on MINI 42 30 7–12 weeks GAD-7, DERS, FFMQ,
HADS, MAIA
Paxling et al. (58) Sweden General–adults GAD diagnosis on SCID-I
PSWQ > 53
GADQ-IV > 5.7











63 42 4 weeks GAD-7, Acceptability, ASI-3,
OASIS, PDSS-SR,
QLES-Q-SF
Repetto et al. (59)
[linked with
(60, 61)]
Italy Primary care–adults GAD diagnosis (unspecified
tool used)
25 24 Not reported GAD-7, PSWQ, BAI,
HAM-A, STAI








Teng et al. (64) Taiwan General–adults GAD diagnosis on DIS-IV
PSWQ > 60
93 82 4 weeks
1 month
PSWQ, BAI, BDI, STAI-S,
STAI-T
Titov et al. (65)
[linked with (66)]
Australia General–adults GAD diagnosis on MINI 34 NR 9 weeks GAD-7, K-10, PHQ-9, SDS
(Continued)
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TABLE 1 | Continued







Titov et al. (67) Australia General–adults Mixed sample
anxiety/depression#
GAD diagnosis on MINI





Topper et al. (68) Netherlands 15- to 22-year-olds PSWQ above 66th
percentile (score 47)






*Patients received active intervention at follow-up timepoint.
♦Study not included in the meta-analysis because it reported only categorical GAD-7 outcomes.
#Outcomes reported separately for GAD sub-group.
##Outcomes reported for the whole mixed sample of common mental health problems but all participants scored GAD7 > 6.
∼Outcomes reported separately for mild GAD sub-group (4 < GAD7 < 10).
++ For the full measure names corresponding to the acronyms, see Appendix E.
modification (52, 53, 64), mindfulness (50, 57), relaxation
(Repetto, 52), and diaphragmatic breathing (12). The most
common technology platform use was a web-interface (n =
17). Two studies used VR platforms (57, 59), and two used
smartphone apps (12, 64). The study by Repetto et al. (59) also
used a mobile interface to enable users to access the VR scenarios
at home but has also included a biofeedback system in one of the
study arms.
DIs differed not only in technology platform and therapy type,
but also in whether additional interpersonal support was offered
as an adjunct to the digital element and, if so, its type. Most DIs
included some interpersonal contact by phone or face-to-face
with professionals (GPs, therapists, psychologists both students
and qualified), non-clinical researchers, or lay people. Only two
studies included DIs that were pure self-help without any contact
(11, 12). Some DIs were supplemented by standardized emails
without regular communication with another person (11, 51, 54).
Selection of Studies and Outcome for the
NMA
A total of 45 different outcome measures were reported in the
included RCTs, as shown in Appendix F. GAD-7 was used in
14 out of the 21 RCTs to measure symptoms at baseline and
outcomes at follow-up. Penn StateWorryQuestionnaire (PSWQ)
(70, 71) was also reported in 14 studies. Apart from GAD-7 and
PSWQ, the two other most frequently reported outcomes were
for depression: the Patient Health Questionnaire−9 item (PHQ-
9) (72) and the Beck Depression Inventory–version II (BDI-II)
(73), reported in 8 and 6 RCTs, respectively (Appendix F1). The
Hamilton Anxiety Scale (HAM-A) (74) used in a recent NMA
on medication for GAD (7), only appeared once in the included
RCTs (Appendix F2).
We focused on GAD-7 as our outcome of choice for the NMA.
GAD-7 is a 7-item anxiety scale described in the literature as a
valid and efficient tool to screen for GAD and assess symptom
severity in clinical practice and research (40).
Our NMA for GAD-7 included 13 studies (Table 1). One
study (54) used GAD-7 but it was not included in the meta-
analysis because it only reported categorical outcomes (i.e.,
mild, moderate, severe) rather than continuous scores. The
measurement period across studies ranged from 3 to 12 weeks,
with longer follow-ups only available for very few studies.
Given the high level of reporting of PSWQ, data for this
outcome was also quantitatively synthesized (see Appendix J).
NMA Results for GAD-7 Scores at
Follow-Up
Ten direct treatment comparisons were made in the 13 trials
included in the GAD-7-based NMA; 4 of the 13 trials were
multi-arm trials [three 3-arm trials (49, 59, 63) and one 5-arm
trial (11)]; five comparisons were informed by more than one
trial where pair-wise ANCOVA meta-analysis was conducted
(ANCOVA FE models and ANCOVA RE for when n > 3).
We constructed a network plot to illustrate which
interventions had been compared head-to-head (direct pairwise
comparisons) for GAD-7 within the 13 included RCTs. An
overview of these pairwise comparisons and synthesized data are
shown in Appendix G. The structure of the network for GAD-7
is shown in Figure 2.
Fixed- and random-effects models were employed with
minimal difference in mean residual deviances and DIC
identified between the models tested. However, posterior
estimates of between-study heterogeneity, τ 2, suggested
considerable variability across studies, which was in line with
the narrative assessment of the studies. Hence, a random-effects
approach was preferred. There was a high degree of uncertainty
in the network results, especially in links not informed by direct
evidence. Table 3 presents the full results of the NMA based on
GAD-7 scores.
Medication (M) was associated with the largest decrease in
GAD-7 median scores compared to the other interventions,
although uncertainty was high in the NMA estimates, with all
95% credible intervals including zero. These results are driven
by the outcomes of a small (n = 21), three-arm, trial (49) that
compared medication supplemented with scheduled face-to-face
meetings with psychologists and GPs, against SDC (a general
health website with scheduled meetings with psychologists &
GPs) and SDI (a web-based CBT self-help programme with
scheduled meetings with psychologists & GPs). The adjustment
for baseline scores indicated that the baseline effect on the final
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TABLE 2 | Characteristics and classifications of interventions and controls in RCTs of digital interventions for GAD.
Study Intervention or control description (mode of delivery, therapy/control method, type of
interpersonal contact/support)
Classification
Andersson et al. (47) 1. Web-based psychodynamic therapy + weekly online support by psychology students/qualified psychologist SDI
2. Web-based CBT + weekly online support by psychology students/qualified psychologists SDI
3. Waiting list (crossover to web-based CBT at 3-months). NI
Andersson et al. (48) 1. Web-based extinction therapy + daily online support by psychology students SDI
2. Waiting list (+ weekly online# PSWQ ratings and option to phone if symptoms worsen–crossover to web-based
extinction therapy at 10 weeks)
NIa
Christensen et al. (11) 1. Web-based CBT–no interpersonal communication UDI
2. Web-based CBT + weekly phone calls by “casual interviewers” SDI
3. Web-based CBT + weekly reminder email similar in content to phone calls by “casual interviewers” but no two-way
communication
UDI
4. Control website (information about general health)–no interpersonal communication UDC
5. Control website (information general health) + weekly phone calls by “casual interviewers” SDC
Christensen et al. (49) 1. Web-based CBT + scheduled on-site meetings with psychologists/GPs SDI
2. Control website (information about general health) + scheduled meetings with psychologists/GPs SDC
3. Medication (SSRI–Sertraline 25 up to 100mg per day) + scheduled meetings with psychologists/GPs M
Dahlin et al. (50) 1. Web-based MBT & ACT + weekly messages via a secure messaging system by psychology students SDI
2. Waiting list (+weekly online# GAD-7 and PSWQ ratings–contact with administrator implied for weekly measure
completion but unclear–crossover to modified web-based MBT & ACT at 9 weeks)
NIa
Dear et al. (51)* 1. Web-based CBT (trans-diagnostic model focusing on mental wellbeing) + weekly phone/email contact with qualified
psychologists
SDI
2. Web-based CBT (GAD-specific focusing on worry control) + weekly phone/email contact with qualified psychologists SDI
3. Web-based CBT (trans-diagnostic model focusing on mental wellbeing) + standardized weekly email reminders and
option to phone/email if needed technical support or had other problems–no scheduled or regular interpersonal contact
UDI
4. Web-based CBT (GAD-specific focusing on worry control) + standardized weekly email reminders and option to
phone/email if needed technical support or had other problems–no scheduled or regular interpersonal contact
UDI
Hazen et al. (52) 1. Computer-delivered attentional retraining + “non-therapy” meetings with “experimenters” every 6 days SDI
2. Sham training + “non-therapy” meetings with “experimenters” every 6 days SDC
Hirsch et al. (53)** 1. Web-based CBM + 1 initial onsite meeting + regular (unspecified) contact by phone/email/SMS with researchers
(unspecified qualifications) + RNT priming
SDI
2. Web-based CBM + 1 initial onsite meeting + regular (unspecified) contact by phone/email/SMS with researchers
(unspecified qualifications)–no RNT priming
SDI
3. Control website (neutral scenarios) + 1 initial onsite meeting + regular (unspecified) contact by phone/email/SMS with
researchers (unspecified qualifications)
SDC
Johansson et al. (55) 1. Web-based psychodynamic therapy + weekly written messages via online messaging system by therapists (unspecified
qualifications)
SDI
2. Waiting list + weekly assessment and non-directive support via online messaging system with therapists (unspecified
qualifications) matching therapist support in the intervention
SDCb
Jones et al. (56) 1. Web-based CBT + weekly messages via online messaging system by therapists (unspecified qualification) SDI
2. Waiting list (crossover after 7– 10 weeks)–no monitoring or other input specified NI
Navarro-Haro et al. (57) 1. Group MBI in weekly onsite meetings with a therapist SNoDI
2. VR mindfulness skills + group MBI in weekly onsite meetings with a therapist SDI
Paxling et al. (58) 1. Web-based CBT (like an online book) + weekly online/email contact with therapist SDI
2. Waiting list (crossover after 8 weeks)–no monitoring or other input specified NI
Pham et al. (12) 1. Mobile game of breathing re-training–no interpersonal contact UDI
2. Waiting list + weekly newsletter with curated content on breathing retraining exercises, matching content to mobile
game, mindfulness meditation (assumed via mobile but not clear) + email reminders to complete assessments
(crossover to access the mobile game after 4 weeks)
UDCc
Repetto et al. (59) 1. VR relaxation during weekly meetings with therapist + mobile phone home-access of VR environments SDI
2. VR relaxation during weekly meetings with therapist + mobile phone home-access ofVR environments + biofeedback
machine for therapist to adapt VR environments according to participant heart rate
SDI
3. Waiting list (no monitoring or any other input specified) NI
Richards et al. (62) 1. Web-based CBT + weekly online messages by psychologists SDI
(Continued)
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TABLE 2 | Continued
Study Intervention or control description (mode of delivery, therapy/control method, type of
interpersonal contact/support)
Classification
2. Waiting list (crossover at week 7–no monitoring or other input) NI
Robinson et al. (63) 1. Web-based CBT + weekly phone/email contact by a “clinician” (clinical psychologist) SDI
2. Web-based CBT + weekly phone/email contact by a “technician” (administrative clinic manager) SDI
3. Waiting list (crossover at week 11–no monitoring or other input) NI
Teng et al. (64) 1. Mobile app–home-delivered ABM + weekly “lab” meeting with assistant + phone call if missed sessions SDI
2. Mobile app–attention training + weekly “lab” meeting with assistant + phone call from if missed sessions SDC
3. Waiting list + weekly meetings with research assistant for matching assessment in a “lab” SNoDCd
Titov et al. (65) 1. Web-based CBT + moderated online discussion forum + instant online messaging + 1 initial phone contact +
subsequent email/phone weekly contact with clinical psychologist
SDI
2. Waiting list (crossover at week 11–no monitoring or other input) NI
Titov et al. (67) 1. Web-based CBT + moderated online discussion forum + instant online messaging + 1 initial phone contact +
subsequent email/phone weekly contact with clinical psychologist
SDI
2. Waiting list (+ unclear if contact with psychologist–crossover at week 9) NI
Topper et al. (68) 1. Group CBT in weekly meetings with psychologists SNoDI
2. Web-based CBT + weekly online personalized feedback from psychologists (unclear whether there was two-way
communication between participant and psychologist in response to feedback).
SDI
3. Waiting list (crossover at 12 months–no monitoring or other input from the research team) NI
# Not clear whether online measures were sent by email or were automated and delivered via a platform.
*2 x 2 factorial RCT, so outcomes reported in 2 groups (SDI vs. UDI for both GAD-specific and transdiagnostic groups).
** Outcomes reported as a single group across both interventions (SDI with or without RNT).
*** Study not included in the meta-analysis because it only reported GAD-7 categorical outcomes.
a“Waiting list” classified as “No Intervention” (NI) because the online weekly ratings were self-completed without any further input from the research team.
b“Waiting list” classified as “Supported Digital Control” (SDC) because there was substantial and regular non-specific support and monitoring via an online messaging system with a
therapist that matched the duration of therapeutic support in the intervention arm.
c“Waiting list” classified as Unsupported Digital Control (UDC) because there was substantial and regular information and therapeutic advice similar to that of the intervention –via the
mobile (inferred) (hence “digital”); standardized materials without two-way interaction with a therapist (hence “unsupported”).
d“Waiting list” classified as Supported Non-Digital Control (SNoDC) because there was substantial and regular face-to-face assessments with a researcher that matched the assessments
of the intervention groups.
ABM, Attentional Bias Modification; ACT, Acceptance and Commitment Therapy; CBT, Cognitive Behavior Therapy; GAD, Generalized Anxiety Disorder; M, medication; MBI, Mindfulness
Based Intervention; MBT, Mindfulness Based Therapy; NI, No intervention; PSWQ, Penn State Worry Questionnaire; RNT, Repetitive Negative Thinking; SDC, Supported Digital Control;
SDI, Supported Digital Intervention; SNoDC, Supported Non-Digital Control; SNoDI, Supported Non-digital intervention; SSRI, Selective Serotonin Reuptake Inhibitor; VR, Virtual Reality;
UDC, Unsupported Digital Control; UDI, Unsupported Digital Intervention.
outcome is small with a 95% credible interval including zero
[change in GAD score:−0.14 (95% CrI−1.10 to 0.82)].
Results of independently pooling direct evidence for each
contrast (but not pooling when n = 1) were found to be
generally consistent with the NMA results, both in terms of
direction and magnitude of the estimates (Table 3, upper-right
triangle, shaded). Of note are the differences in the estimates
found when applying fixed- and random-effects ANCOVAmeta-
analysis model on direct evidence for the comparisons of SDIs vs.
SDCs (n= 4) and SDIs vs. NI (n= 8), evidencing non-negligible
variability across studies and the importance of accounting for
between-study heterogeneity.
Based on SUCRA values and rankograms for each
intervention, as detailed in Appendices H1, H2, respectively,
SDIs were estimated to be more effective (i.e., ranked higher)
than UDIs, which included unsupported web-based CBT (11, 51)
and an unsupported mobile breathing retraining game (12);
however SDIs were less effective than SNoDI, a weekly group
mindfulness-based intervention with a therapist (57).
Similar analysis was performed on the PSWQ outcome.
Results are shown in Appendix J.
Results of Between-Study Heterogeneity
and Inconsistency Assessments
Three sources of heterogeneity were considered relevant: disease
severity, concomitant medication, and comorbidities. Using data
relating to disease severity and comorbidities was not feasible–
seeAppendix I for further details–thus only data on concomitant
medication was included as a covariate in the synthesis modeling.
When this covariate is included, the between-study heterogeneity
parameter, τ 2, is not reduced, suggesting that heterogeneity
is not explained by this covariate. Crucially, even if the
proportion receiving concomitant medication was identified
as an important effect modifier, the meta-regression model
is not necessarily suited to detect this intervention-covariate
interaction as patients were receiving medication before trial
entry. Therefore, medication may have already exerted an
effect on patients, being captured by the ANCOVA baseline
adjustment component.
Several data loops existed in the network, where both
direct and indirect data informed intervention effectiveness
estimates; the possibility of inconsistencies was investigated.
Table 3 showed no evidence of substantial discrepancies between
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FIGURE 2 | Network plot for comparisons between all interventions and controls for GAD populations in RCTs with GAD-7 score. GAD, Generalized Anxiety Disorder;
M, medication; NI, No intervention; SDC, Supported Digital Control; SDI, Supported Digital Intervention; SNoDI, Supported Non-digital intervention; UDC,
Unsupported Digital Control; UDI, Unsupported Digital Intervention. Line thickness around the node: proportional to the number of patients contributing to each
intervention/control group. Line thickness connecting nodes: proportional to the number of patients contributing to each pairwise comparison between
interventions/controls. n, number of trials informing each comparison.
TABLE 3 | Full meta-analysis results: network and direct pairwise comparisons between all interventions and controls for post-treatment (12 weeks) GAD-7 scores
adjusted for baseline.
FE, Fixed Effects; GAD, Generalized Anxiety Disorder; M, medication; NI, No intervention; RE, Random Effects; SDC, Supported Digital Control; SDI, Supported Digital Intervention;
SNoDI, Supported Non-digital intervention; UDC, Unsupported Digital Control; UDI, Unsupported Digital Intervention.
*Non-pooled data for when n = 1.
**Pairwise ANCOVA RE meta-analysis for when n > 3 for contrasts with intervention SDI.
Lower left triangle: Network Meta-Analysis Results (ANCOVA RE); Upper right triangle (shaded area): Direct Pairwise Meta-Analysis Results (ANCOVA FE); Cells with thick black perimeter:
available comparisons between digital interventions (supported and unsupported) and alternatives.
the direct and the NMA results; given the uncertainty in the
data, only very large differences were likely to result in statistical
significance. Results of the consistency and inconsistency models
indicated the existence of overall model consistency, as detailed
in Appendix I.
Similar analysis was performed on the PSWQ outcome.
Results are shown in Appendix J.
Sensitivity Analysis Results
The sensitivity of the network to specific studies was investigated.
In total, 10 analyses with 12 (rather than the total 13) included
studies for GAD-7 were performed, and the probability of each
intervention being the best was assessed. The SSRI and group
CBT continued to have the highest chances of being “best,” with
probabilities of around 43 and 30%, respectively.
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Two studies (49, 59) had <30 patients. Excluding these
studies from the network also removed medication (M) from
the comparator set, altering the network structure. As expected,
with the reduction in the number of studies informing the
network, the uncertainty in the posterior effect distributions
increased further. However, no significant changes were observed
compared to the main model results.
Similar analysis was performed on the PSWQ outcome. The
ranking of active interventions in terms of median PSWQ score
decrease vs. no intervention (NI) was unaltered, although higher
score decreases were estimated. Comparing the direction and
magnitude of differences in median scores at follow-up between
GAD-7 and PSWQ results (where available for both), we make
three observations (Appendix K). First, the difference in GAD-7
median scores at follow-up between medication and DIs is the
largest across all comparators and favors medication. Second,
there were no data available for comparisons between DIs
and individual therapy, either face-to-face or by telephone, or
between DIs and manualized guided self-help (which is the non-
digital counterpart of most DIs). Third, the direction of effect
favored SDIs for GAD-7 and UDIs for PSWQ.
DISCUSSION
Summary and Interpretation
Our systematic review retrieved 21 RCTs of DIs or alternative
pathways of care, including no intervention, for GAD.
Comparators included in the studies varied. Specifically,
interventions or controls could be digital or non-digital and
supported or unsupported by clinicians or lay people. The
majority of comparisons were between supported digital
interventions and no intervention. Using an ANCOVA
framework, our main NMA on GAD-7 pooled together post-
treatment scores–adjusted for baseline. In addition, the existence
of treatment effect modifiers was assessed, several sensitivity
analyses were carried out and network consistency evaluated.
NMA on the PSWQ outcome was also performed.
Our NMA results suggest that medication is associated
with lower anxiety scores at follow-up relative to all other
interventions and controls. Medication also ranks first in terms
of its likelihood of being most effective, which considers the
uncertainty in relative effect estimates. Medication results are
based on data from one study. Antidepressant medication as a
treatment for GAD is supported by clinical guidelines (75) and
previous evidence syntheses. A large NMA (7) of medication
against placebo for GAD found that Sertaline (the same
antidepressant used in the study by Christensen et al. included
in our NMA) improved HAM-A scores by a mean difference of
−2·88 (CrI−4·17 to−1·59) from baseline compared to a placebo
based on six trials. Another meta-analysis involving a mixed
population (13) favored a combined treatment of psychological
therapy and medication for all depressive and anxiety disorders,
except GAD, where the direction of effect favored antidepressant
medication (Venlafaxine) alone.
Previous reviews of DIs that reported GAD-related outcomes
(13, 14) used mixed samples of anxiety disorders and depression,
without reporting outcomes separate for GAD subgroups. There
are no RCTs with GAD populations comparing DIs with non-
digital self-help interventions based on a manual rather than a
web-based program. Also, no RCTs compare DIs with individual
therapy for GAD, either face-to-face or by telephone; the only
available comparisons in the literature are between DIs and
group therapy.
Due to very wide confidence intervals, our NMA results were
inconclusive as to whether DIs for GAD were better than no
intervention or non-therapeutic active controls, or whether they
confer an additional benefit to standard therapy. Previous meta-
analyses have suggested that supported DIs could be as good
as face-to-face therapy across depression, anxiety, and somatic
disorders (76, 77). However, the mixed samples in these meta-
analyses without separate analysis or reporting for GAD sub-
samples does not allow any conclusions about the relative efficacy
of DIs specific to the treatment and prevention of GAD.
The results for supported vs. unsupported DIs for GAD were
counterintuitive, as we would expect supported DIs to rank
higher in terms of the likelihood of being “best,” based on a
previous meta-analysis in which supported DIs were found to be
four times more likely to be effective compared to those without
any therapist contact (78). We found that unsupported DIs rank
higher than supported DIs in terms of the probability of being
best, but vice versa when considering all rankings (SUCRAs).
This is consistent with a recent review (79) that reported mixed
findings regarding guided vs. unguided DIs and human vs.
automated support for DIs. This suggests that the design, content,
technology platform or type of reinforcement offered in lieu of
personal support in unsupported DIs may be important and
account for some of the variability in outcomes.
Strengths and Limitations
To our knowledge this is the first ANCOVA NMA model to
synthesize evidence on two widely used outcomes for GAD.
Our NMA makes best use of all currently available RCT-based
evidence on DIs for GAD. Despite the sparse and low-quality
data, a statistical synthesis can still be useful for decision-makers
in mental health (including healthcare professionals, providers
and policy-makers, patients and their families, and the research
community) who may be considering the use of DIs for GAD,
so that they are properly informed about the current status of
the evidence base, know which DIs have been shown to be more
effective in reducing GAD and prioritize future research.
There was substantial uncertainty around effect estimates
of DIs against alternatives for GAD-7. This is driven by the
small number of studies informing most comparisons, the small
sample sizes used in some of these studies and their high risk
of bias across the evidence base, all limiting our confidence in
any observed differences in anxiety scores between intervention,
comparators, and control arms. These observed differences may
simply be due to chance; but in view of the current evidence
base we cannot make clear recommendations about the relative
effectiveness of DIs against their comparators.
We have to use caution when interpreting the results of our
NMA across all different interventions for GAD. Our review
has been completed in the context of DIs; it only included
RCTs in which at least one of the randomisation arms was
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a DI. Therefore, we cannot draw any conclusions about the
comparative merit of non-digital interventions (psychological or
pharmacological) for GAD when these are considered separately
to DIs (for example group CBT vs. medication). To be able
to do this, we would need to include RCTs in an NMA that
would enable 2nd or 3rd order contrasts (e.g., RCTs comparing
no intervention and medication), which was beyond the scope
of this review. Also, ranking based on likelihood of being best
and on SUCRAs does not reflect differences in effectiveness
estimates between interventions and controls and credible
intervals, that is, we cannot tell whether the differences between
ranking position (e.g., between 1st, 2nd, 3rd, 4th, etc.) are
clinically meaningful.
Another point of caution, as with all evidence synthesis of
complex interventions, is the pooling DIs and their alternatives
into groups for analysis based on our classification criteria.
Any classification implies interpretation and judgement which
is conditional upon the information available from included
studies. We note the insufficient reporting of details about
“non-therapeutic controls” and waiting list in some studies.
Furthermore, we could have split DIs into further categories
according to the technology used (e.g., VR, internet, mobile
app), or the function of the technology (e.g., adjunct to
clinician-delivered therapy vs. patient self-help), or the type
of support (e.g., phone calls vs. meetings). This would
have created more “nodes” in the NMA models, but also
more uncertainty because comparisons between DIs and their
alternatives within each subgroup would have been informed by
fewer studies.
Many of the included RCTs recruited small samples and
involved multiple arms, often comparing different versions of
the same intervention, thereby reducing the power of the study.
Our evidence synthesis also shows that the majority of RCTs
have either a short timeframe for follow-up (up to 12 weeks), or
the control group has already crossed to the intervention at the
point of a longer follow-up (up to 2 years), which undermines
the original randomisation. Consequently, we did not include
observations for further follow-up time points, where these were
available, nor did we account for time differences in the short-
term outcome reporting (post- treatment assessments varied
from 3 to 12 weeks). Our NMA results reflect the short-term
impact of DIs over an initial treatment period, but there is scant
evidence to inform randomized comparisons about effectiveness
beyond 12 weeks.
Recommendations
As GAD is the most prevalent and least studied condition
among other common mental health problems, future evidence
syntheses will be helpful to focus on GAD populations and
stratified GAD subgroups where these are randomized within
mixed populations, as means of informing GAD-specific future
research and clinical guidelines (75). Feasibility and pilot
studies, as well as user involvement in the development of
the intervention and delivery protocols, could ensure that
the final RCT tests the best possible intervention for GAD.
Adaptive designs with improved intervention features and
boosted recruitment numbers to a fully powered RCT are
preferable to the underpowered studies with multiple arms
testing increments of the same DI that we have identified.
Our NMAs and previous literature suggest that
antidepressants are an important factor to consider in future
studies on DIs for GAD. Psychological interventions–whether
digital or non-digital–include participants who are taking
medication as part of routine care. It is difficult to disentangle
the effects of medication and psychological support for GAD,
and future RCTs need to report medication details (name, dose,
and duration) and include it as a covariate in their analysis to
establish how outcomes with DIs and controls are influenced by
concurrent medication use.
The evidence base available in this setting is complex. In
particular, the sheer volume of anxiety metrics (45 in total) being
reported across the available studies, suggests a lack of consensus
on which measures to use in evaluating GAD outcomes.
Having a consensus about GAD-specific outcome measures can
prevent participant fatigue from completing batteries of different
questionnaires and enable comparisons across studies and data
synthesis. GAD-7 is more sensitive to changes associated with
treatment and therefore may be more suitable for longitudinal
clinical research (80). Reporting continuous data on the GAD-
7 as a common measure in RCTs with GAD populations will
make more studies available for a future statistical synthesis.
Including HAM-A in studies of psychological therapies will
enable us to compare results with pharmacological studies.
Future analyses using multivariate models may be able to make
better use of the available evidence by borrowing strength across
different outcomes.
Many studies that follow up participants over the longer-term
offer the intervention to those randomized to the control group
at a crossover point. Many studies that follow up participants
over the longer term offer the intervention to those randomized
to the control group at a crossover point, potentially biasing
any long-term treatment effect (81). Participants are also likely
to receive some treatment as part of usual care the longer they
remain on waiting lists or non-therapeutic controls, so studies
cannot withhold interventions to enable long-term follow-up.
As the typical duration of DIs is between 3 and 12 weeks, the
follow-up period of future RCTs needs to be longer, for example 6
months, to help us better understand the “stickiness” longer term
effects of DIs beyond their initial delivery period. Usual care and
waiting lists are poorly reported in RCTs and do not include data
on concurrent interventions accessed by participants, including
openly available self-help, which can influence the observed
difference in outcome between DIs and no intervention. Greater
clarity and more detailed reporting about the specific elements
of comparators is essential to improve our understanding of the
effects of DIs.
CONCLUSIONS
This study is the first to evaluate the effectiveness of DIs
specifically in a GAD population. It is also the first to
combine all the RCT-based effectiveness evidence from DIs
and key comparators in a single modeling framework, allowing
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the estimation of relative treatment effects for all relevant
comparisons. Our results suggest that antidepressant medication
is associated with lower anxiety scores at follow-up relative to
all other interventions and controls. Results were inconclusive
as to whether DIs are better than no intervention and non-
therapeutic active controls for GAD, or whether they confer an
additional benefit to standard therapy. Overall, our findings are
limited in informing decision-making, highlighting how little
is currently known about the comparative effectiveness of such
interventions. Future primary studies and meta-analyses need
to focus on GAD populations rather than mixed samples, or
report outcomes specifically for GAD sub-samples if they intend
to answer questions about the comparative effectiveness of DIs
for GAD. Comparing DIs with manualized (non-digital) self-
help and individual therapy, for which there are no current RCTs
for GAD populations, will be useful in the context of stepped
care. Antidepressant medication for GAD as a first-line treatment
against DIs deserves further research and economicmodeling. To
inform commissioning and potential disinvestment from non-
digital alternatives, we need to put the findings of this evidence
synthesis into context together with an assessment of the costs of
developing and implementing DIs in clinical practice.
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